Rifadin Related Published Studies
Well-designed clinical trials related to Rifadin (Rifampin)
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. [2011.04]
Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. [2011.03]
[Evaluation years in leprosy patients treated with single dose alternative scheme ROM (rifampin, ofloxacin, minocycline), after seven to nine]. [2010.11]
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. [2010.10]
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. [2010.09]
Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. [2010.07]
A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. [2009.10]
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. [2009.06]
Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. [2009.06]
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. [2008.11.18]
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. [2008.01]
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. [2007.07]
The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. [2007.03.31]
Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. [2007.03]
Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. [2007.01.15]
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. [2006.11]
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. [2006.10]
Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. [2006.09.01]
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. [2006.04.15]
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. [2005.08]
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. [2005.08]
Potential for interactions between caspofungin and nelfinavir or rifampin. [2004.11]
Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. [2004.10]
Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. [2004.10]
Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. [2004.09.18]
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. [2004.09]
Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. [2004.08.15]
Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. [2004.08.01]
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. [2004.05]
Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. [2004.03]
A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. [2004.03]
Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. [2003.12]
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. [2003.10]
Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. [2003.05]
Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. [2002.11]
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. [2002.03]
Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. [2001.10]
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. [2001.08]
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. [2001.06]
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. [2000.12]
Rifampin decreases the plasma concentrations and effects of repaglinide. [2000.11]
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. [2000.05]
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. [2000.03.15]
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. [1999.04]
The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. [1999.04]
Risk factors for rifampin-monoresistant tuberculosis: A case-control study. [1999.02]
Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. [1999.01]
Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. [1999.01]
Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. [1999]
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. [1998.12]
Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. [1998.09]
Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. [1998.05.20]
Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. [1998.02]
A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. [1998.01.15]
Rifampin reduces plasma concentrations and effects of zolpidem. [1997.12]
Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. [1997.12]
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. [1997.12]
Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. [1997.08.15]
Loss of analgesic effect of morphine due to coadministration of rifampin. [1997.08]
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. [1997.05]
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. [1997.05]
Triazolam is ineffective in patients taking rifampin. [1997.01]
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. [1996.08.08]
Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. [1996.08]
A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. [1996.05]
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. [1996.01]
Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. [1995.11]
Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. [1995.09]
Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. [1994.12]
Activity of two doses of rifampin against Mycobacterium leprae. [1994.09]
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. [1994.07]
Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. [1993.09]
Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. [1993.07]
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. [1993.06]
Comparative efficacy of oral rifampin and topical chloramphenicol in eradicating conjunctival carriage of Haemophilus influenzae biogroup aegyptius. Brazilian Purpuric Fever Study Group. [1992.09]
A randomized controlled trial of perioperative rifampin/trimethoprim in cerebrospinal fluid shunt surgery. [1992.08]
Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. [1992.07.01]
Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. [1992.03]
Duration of rifampin chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type B. [1992.03]
A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. [1992.03]
Influence of rifampin on the pharmacokinetics of pefloxacin. [1991.12]
Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. [1991.11.01]
Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. [1991.08]
Induction of fluconazole metabolism by rifampin: in vivo study in humans. [1991.04]
Treatment of pruritus of primary biliary cirrhosis with rifampin. [1991.02]
Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. [1990.10]
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report. [1990.06]
Failure of rifampin to relieve pruritus in chronic liver disease. [1990.04]
Rifampin relieves pruritus in children with cholestatic liver disease. [1990.04]
Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. [1990.03]
Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. [1989]
Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections. [1988.06]
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. [1988.02]
Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin. [1987.07]
Well-designed clinical trials possibly related to Rifadin (Rifampin)
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. [2011.12]
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2011.09.07]
New regimens to prevent tuberculosis in adults with HIV infection. [2011.07.07]
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. [2011.07]
Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. [2011.06]
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. [2011.06]
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. [2011.05]
|
